-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$2.70190.32% Upside
Homology Medicines, Inc. Frequently Asked Questions
-
What analysts cover Homology Medicines, Inc.?
Homology Medicines, Inc. has been rated by research analysts at Credit Suisse in the past 90 days.